亿腾嘉和(06998.HK)：EDP167 II期临床试验完成首例受试者给药

Core Viewpoint - Eton Pharma (06998.HK) has successfully completed the first dosing of a subject in the Phase II clinical trial for its small nucleic acid innovative drug EDP167, targeting adult patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - The Phase II clinical trial for EDP167 is a multi-center, dose-exploration, open-label study [1] - The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients [1] - The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] Group 2 - The primary endpoint assessment is expected to be completed by the fourth quarter of 2026 [1]